DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class, Structures, Indications, Mode of Action” report has been added to ResearchAndMarkets.com’s offering.
The glycomic therapeutics market in Asia Pacific is expected to grow from US$ 12,950.82 million in 2022 to US$ 34,592.83 million by 2028; it is estimated to grow at a CAGR of 17.8% from 2022 to 2028.
Glycomics has the potential to bring new perspectives to precision medicine, which is currently dominated by genetic and proteomic tools. Therefore, the high adoption of glycomics in various therapeutic areas would propel the demand for these techniques in the coming years. Nonetheless, ongoing research and developments and clinical advancements in the field of therapeutics are expected to create lucrative growth opportunities for the glycomics therapeutics market during the forecast period.
Market Overview
Asia Pacific (APAC) is the fastest-growing market for glycomic therapeutics. The Asia Pacific glycomics therapeutics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is likely to account for ~11.89% share of the global glycomic therapeutics market in 2022 owing to the improving government support in countries, collaboration of research organizations, rising glycomics research institutes, and advancing healthcare infrastructure.
Therefore, the region offers several opportunities for the glycomic therapeutics market players to grow during the forecast period.
Asia Pacific Glycomic Therapeutics Market Segmentation
The Asia Pacific glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
- Based on class, the Asia Pacific glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022.
- Based on structure, the Asia Pacific glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022.
- Based on indications, the Asia Pacific glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, alzheimer’s disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022.
- Based on mode of action, the Asia Pacific glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022.
- Based on country, the Asia Pacific glycomic therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Bayer AG; Alzheon, Inc.; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics market in Asia Pacific.
Key Topics Covered:
1. Introduction
2. Asia Pacific Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
4. Asia Pacific Glycomic Therapeutics Market – Market Landscape
5. Asia Pacific Glycomic Therapeutics Market – Key Market Dynamics
6. Glycomic Therapeutics Market- Asia Pacific Analysis
7. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
8. Asia Pacific Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication
9. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures
10. Asia Pacific Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action
11. Asia Pacific Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis
12. Glycomic Therapeutics Market -Industry Landscape
13. Company Profiles
14. Appendix
Companies Mentioned
- Biomarin Pharmaceutical Inc.
- Genzyme Corporation (Sanofi)
- Bayer Ag
- Glaxosmithkline Plc.
- F. Hoffmann-La Roche Ltd
For more information about this report visit https://www.researchandmarkets.com/r/vmxmh4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900